C. Roehrborn, Three months??? treatment with the ??1-blocker alfuzosin does not affect total or transition zone volume of the prostate, Prostate Cancer and Prostatic Diseases, vol.60, issue.suppl 6A, pp.121-126, 2006.
DOI : 10.1046/j.1365-2125.1998.00636.x

C. Roehrborn, P. Siami, and J. Barkin, The Effects of Combination Therapy with Dutasteride and Tamsulosin on Clinical Outcomes in Men with Symptomatic Benign Prostatic Hyperplasia: 4-Year Results from the CombAT Study, European Urology, vol.57, issue.1, pp.123-154, 2010.
DOI : 10.1016/j.eururo.2009.09.035

J. Mcconnell, R. Bruskewitz, and P. Walsh, The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment among Men with Benign Prostatic Hyperplasia, New England Journal of Medicine, vol.338, issue.9, pp.557-63, 1998.
DOI : 10.1056/NEJM199802263380901

J. Mcconnell, C. Roehrborn, and O. Bautista, The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia, New England Journal of Medicine, vol.349, issue.25, pp.2387-98, 2003.
DOI : 10.1056/NEJMoa030656

R. Rittmaster, R. Norman, and L. Thomas, Evidence for atrophy and apoptosis in the prostates of men given finasteride, J Clin Endocrinol Metab, vol.81, pp.814-823, 1996.

M. Naslund and M. Miner, A review of the clinical efficacy and safety of 5??-reductase inhibitors for the enlarged prostate, Clinical Therapeutics, vol.29, issue.1, pp.17-25, 2007.
DOI : 10.1016/j.clinthera.2007.01.018

H. Autorité and . Santé, Synthèse d'avis de la commission de la transparence (Avodart, Combodart, Chibro-Proscar) -Avis favorable au remboursement, uniquement en deuxième intention dans le traitement de l'hypertrophie bénigne de la prostate, 2012.

. Published-online and . First, www.has-sante.fr/portail, 2012.

I. Thompson, P. Goodman, and C. Tangen, The Influence of Finasteride on the Development of Prostate Cancer, New England Journal of Medicine, vol.349, issue.3, pp.215-239, 2003.
DOI : 10.1056/NEJMoa030660

G. Andriole, D. Bostwick, and O. Brawley, Effect of Dutasteride on the Risk of Prostate Cancer, New England Journal of Medicine, vol.362, issue.13, pp.1192-202, 2010.
DOI : 10.1056/NEJMoa0908127
URL : https://hal.archives-ouvertes.fr/hal-00493661

C. Roehrborn, G. Andriole, and T. Wilson, Effect of Dutasteride on Prostate Biopsy Rates and the Diagnosis of Prostate Cancer in Men with Lower Urinary Tract Symptoms and Enlarged Prostates in the Combination of Avodart and Tamsulosin Trial, European Urology, vol.59, issue.2, pp.244-253, 2011.
DOI : 10.1016/j.eururo.2010.10.040

N. Fleshner, M. Lucia, and B. Egerdie, Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial, The Lancet, vol.379, issue.9821, pp.1103-1114, 2012.
DOI : 10.1016/S0140-6736(11)61619-X

L. Määttänen, A. Auvinen, and U. Stenman, European randomized study of prostate cancer screening: first-year results of the Finnish trial, British Journal of Cancer, vol.79, issue.7-8, pp.1210-1214, 1999.
DOI : 10.1038/sj.bjc.6690194

T. Murtola, T. Tammela, and L. Määttänen, Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer Screening Trial, British Journal of Cancer, vol.98, issue.5, pp.843-851, 2009.
DOI : 10.1056/NEJMoa030660

D. Robinson, H. Garmo, and A. Bill-axelson, Use of 5??-reductase inhibitors for lower urinary tract symptoms and risk of prostate cancer in Swedish men: nationwide, population based case-control study, BMJ, vol.346, issue.jun18 2, p.3406, 2013.
DOI : 10.1136/bmj.f3406

M. Preston, K. Wilson, and S. Markt, 5??-Reductase Inhibitors and Risk of High-Grade or Lethal Prostate Cancer, JAMA Internal Medicine, vol.174, issue.8, pp.1301-1308, 2014.
DOI : 10.1001/jamainternmed.2014.1600

A. Palmaro, G. Moulis, and F. Despas, Overview of drug data within French health insurance databases and implications for pharmacoepidemiological studies, Fundamental & Clinical Pharmacology, vol.54, issue.Suppl 1, pp.616-640, 2016.
DOI : 10.1097/MLR.0000000000000471

P. Tuppin, L. Pestel, and S. Samson, Poids humain et ??conomique des cancers en France en 2014, les donn??es du Sniiram, Bulletin du Cancer, vol.104, issue.6, pp.524-561, 2017.
DOI : 10.1016/j.bulcan.2017.01.010

M. Colonna, A. Danzon, and P. Delafosse, Cancer prevalence in France: Time trend, situation in 2002 and extrapolation to 2012, European Journal of Cancer, vol.44, issue.1, pp.115-137, 2008.
DOI : 10.1016/j.ejca.2007.10.022
URL : https://hal.archives-ouvertes.fr/inserm-00332710

J. Pogue, P. Devereaux, and L. Thabane, Designing and Analyzing Clinical Trials with Composite Outcomes: Consideration of Possible Treatment Differences between the Individual Outcomes, PLoS ONE, vol.355, issue.98, p.34785, 2012.
DOI : 10.1371/journal.pone.0034785.s001

J. Epstein, M. Zelefsky, and D. Sjoberg, A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score, European Urology, vol.69, issue.3, pp.428-463, 2016.
DOI : 10.1016/j.eururo.2015.06.046